Case Series : Management of Elevated Lipoprotein(a) Using Double-Filtration Plasmapheresis (DFPP) in Hemodialysis Patients With Chronic Kidney Disease ; ( LiPo-A )

Case Series : Management of Elevated Lipoprotein(a) Using Double-Filtration Plasmapheresis (DFPP) in Hemodialysis Patients With Chronic Kidney Disease Clinical and Biological Outcomes in Patients at Cardiovascular and Thromboembolic Risk

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07390604

Acronym

LiPo-A

Enrollment

Registered

2026-02-05

Start date

2025-07-01

Completion date

2025-12-31

Last updated

2026-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Double-filtration Plasmapheresis, End Stage Chronic Renal Failure, Hemodialysis Complication, Lipoprotein(a), Lipoprotein-apheresis

Brief summary

Lipoprotein-apheresis DFPP has been performed in patients with Lp(a) levels greater than 125 nmol/L. In this report, data will be presented on five hemodialysis patients with significantly elevated Lp(a) levels (\>200 nmol/L) who had a history of cardiovascular disease and notable thromboembolic events.

Detailed description

The biological and clinical outcomes related to Lipoprotein-apheresis DFPP treatment and the associated cardiovascular and thromboembolic events will be described in these patients. Additionally, the impact of DFPP on biological and clinical markers including LDL cholesterol, triglycerides, fibrinogen, hemoglobin, platelet count, C-reactive protein (CRP), blood pressure, plasma volume treated, volume of albumin substitution, volume of plasma rejected, and duration of each Lipoprotein-apheresis DFPP session will be evaluated .

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Chronic hemodialysis patients with elevated Lp(a) levels (\>200 nmol/L) and a history of cardiovascular disease and/or thromboembolic events who underwent DFPP sessions as part of their management

Exclusion criteria

* -Patients with progressive, active disease, presenting with severe general deterioration and a limited life expectancy * Patients presenting with hemodynamic instability * Patients presenting with acute kidney diseases.

Design outcomes

Primary

Measure	Time frame	Description
serum Lp(a) concentration (nmol/L), on routine venous blood sampling	up to 15 months after inclusion	Before and after each DFPP session (repeated measures) during the study period

Secondary

Measure	Time frame	Description
serum LDL and serum triglycerides concentration (g/L), on routine venous blood sampling	up to 15 months after inclusion	before and after each DFPP session (repeated measures) during the study period
serum triglycerides concentration (g/L), on routine venous blood sampling	up to 15 months after inclusion	before and after each DFPP session (repeated measures) during the study period
cardiovascular or thromboembolic events	during all the study period: up to 15 months after inclusion	Myocardial infarction, stroke, Deep vein thrombosis, Pulmonary embolism, Systemic arterial embolism, aortiques complictions, thrombosis, Based on patient questioning and clinical examination during routine follow-up consultations
Hemodynamic status:blood pressure	up to 15 months after inclusion	follow-up of patients' blood pressure (mmHg) before and after each DFPP session (repeated measures) during the study period
Hemodynamic status: ultrafiltration rate	up to 15 months after inclusion	follow-up of patients' ultrafiltration rate (grams) before and after each DFPP session (repeated measures) during the study period

Countries

France

Contacts

PRINCIPAL_INVESTIGATORZead TUBAIL, MD

CHR Metz-Thionville Hopital de Mercy

Outcome results